Clinical trial · Interventional
Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor
An Open-label, Multi-center，Phase II Study of Camrelizumab Combined With Famitinib in the Treatment of Advanced Solid Tumor
NCT04346381CI-TRIAL-00069670completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an open-label, multi-center study to evaluate the anti-tumor activity and safety of camrelizumab combined famitinib in subjects with selected advanced solid tumor.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Camrelizumab | Drug | Camrelizumab | ALIAS |
| Famitinib | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- camrelizumab combined with famitinib
- description
- Participants will receive camrelizumab on Day 1of each cycle and famitinib qd up to 2 years.
- interventionNames
- Drug: Camrelizumab
- Drug: Famitinib
Primary outcomes (1)
- measure
- Response Rate
- timeFrame
- Up to 18 months
- description
- Response Rate
Secondary outcomes (10)
- measure
- PFS
- timeFrame
- Up to 18 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histologically- or cytologically-confirmed diagnosis of advanced solid tumor. 2. Willing to provide tumor tissue for PD-L1 biomarker analysis. 3. At least one measurable lesion according to RECIST 1.1. 4. ECOG performance status of 0 to 1. 5. Life expectancy of more than 12 weeks. 6. Signing the informed consent forms. 7. Adequate bone marrow, liver and renal function. Exclusion Criteria: 1. Subjects with untreated central nervous system (CNS) metastases. 2. Subjects with an active, known or suspected autoimmune disease. 3. Subjects with clinically significant cardiovascular and cerebrovascular diseases. 4. Subjects with high blood pressure who cannot be controlled well with antihypertensive drugs. 5. Subjects with previous digestive tract bleeding history within 3 months or evident gastrointestinal bleeding tendency. 6. Subjects with arterial / venous thrombosis events occurred within 6 months of the first dose. 7. Subjects who have previously received anti-PD-1 / PD-L1 monoclonal antibody, anti-CTLA-4 monoclonal antibody, and VEGFR small molecule inhibitor therapy.
References
Publications (4)
- DERIVEDXu B, Zhu G, Lu J, Zhang X, Chen X, Liu Q, Qu S, Fan J, Liu T. Camrelizumab Plus Famitinib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Study. Cancer Med. 2026 May;15(5):e71899. doi: 10.1002/cam4.71899. PMID 42165088
- DERIVEDAi L, Li Q, Zhang S, Dong Y, Yang M, Li J, Pan Y, Yuan Y, Yi S, Wang J, Cheng Y, Feng J, Gao S, Wang X, Qu S, Zhang X, Lu J, Xiu P, Wang S, Yang X, Yu Y, Liu T. Famitinib plus camrelizumab in patients with advanced colorectal cancer: Data from a multicenter, basket study. Innovation (Camb). 2025 Jan 6;6(1):100745. doi: 10.1016/j.xinn.2024.100745. eCollection 2025 Jan 6. PMID 39872476
- DERIVEDRen S, Wang X, Han BH, Pan Y, Zhao J, Cheng Y, Hu S, Liu T, Li Y, Cheng Y, Feng J, Yi S, Gu S, Gao S, Luo Y, Liu Y, Liu C, Duan H, Wang S, Yang X, Fan J, Zhou C. First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS >/=1%: results from a multicenter, open-label, phase 2 trial. J Immunother Cancer. 2024 Feb 21;12(2):e007227. doi: 10.1136/jitc-2023-007227. PMID 38388167
- DERIVEDDing X, Hua YJ, Zou X, Chen XZ, Zhang XM, Xu B, Ouyang YF, Tu ZW, Li HF, Duan CY, Zhang WJ, You R, Liu YP, Liu YL, Yang Q, Huang PY, Wang SN, Fan J, Chen MY. Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study. EClinicalMedicine. 2023 Jun 23;61:102043. doi: 10.1016/j.eclinm.2023.102043. eCollection 2023 Jul. PMID 37415845